RxDoctor Payments Data

Akram Audi, MD

Nephrology · Tampa, FLNPI 1265841092

Payments from drug & device makers

$437in general payments, 2019–2025

Across 9 payments — averaging $48.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$182
  • AstraZeneca$113
  • Bayer$102
  • AbbVie$26
  • Daiichi Sankyo Inc.$13

What the payments were for

  • Food & beverage$28866%
  • Other$14934%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Baxter Healthcare3$182
AstraZeneca2$113
Bayer1$102
AbbVie2$26
Daiichi Sankyo Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$437 in reported general payments places this provider in the 20th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$194,360
Medicare patients
435
Services billed
1,407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol94$104,346
ProsolParenteral Amino Acid 20% No.1150$29,608
KerendiaFinerenone14$16,564
JardianceEmpagliflozin17$15,938
Sevelamer Carbonate54$10,405
ClinolipidFat Emulsion/Olive/Soy/Phospho28$8,871
Calcium Acetate88$4,953
Potassium Chloride141$4,166
Torsemide57$2,293
ClinisolParenteral Amino Acid 15% No.511$2,233
Bumetanide40$2,104
Nifedipine ErNifedipine44$1,349
Potassium Citrate ErPotassium Citrate16$1,338
Furosemide195$1,286
Irbesartan85$1,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$113$104,34694 claims
BayerKerendia$102$16,56414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 756 nephrology providers in Florida.

Other nephrology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →